NCT04744363View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

PHASE1CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

March 19, 2022

Study Completion Date

March 19, 2022

Conditions
Psoriasis
Interventions
DRUG

Stelara PFS

Pre filled syringes filled with AVT04 and Stelara

Trial Locations (4)

1010

ACS, Auckland

3004

Nucleus Network Melbourne, Melbourne

8011

CCST, Christchurch

Unknown

Nucleus Network, Brisbane

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

Alvotech Swiss AG

INDUSTRY